About Event

 

The PREDiCT: 9th Annual Tumour Models Summit will return to London this December.

This 3-days summit is the definitive preclinical community for translational experts to assess updates on emerging models, compare human vs model systems and exchange ideas with key model developers. Through adopting the right preclinical platforms for your studies, you will be able to accelerate your immuno-oncology molecule into clinic, while ensuring safety, efficacy and minimising adverse effects for patients. Join us in December and learn how to avoid trial-and-error and embrace new complex models which will subsequently empower your clinical decisions!

 

Selection of topics up for discussion this December:

Humanised Mouse

Humanized Mouse Models

Explore insight into the response of immunotherapies in different humanised mouse models. Case studies from Immatics and Genmab will assist in choosing the right humanised mouse model for your study, limitations in transability into humans, interpreting data read outs, minimizing overestimation of efficacy, and evidence to show the immune response is generated by adaptive immunity.

GEMMs

GEMM’s

Tumours arising in advanced GEMMs can closely mimic the histopathological and molecular features of their human counterparts. However, these models take a long time to generate tumours, and can be variable. Roche and Molecular Biotechnology Centre explore their advances and discuss in what instances should you choose GEMM?

Syngeneic and PDX

3D Models

3D models can mimic some of the challenges faced in the real patient, recapitulating the tumour microenvironment and micro-architecture, giving good prediction of in vivo and clinical drug response, so why the slow adoption? GSK and Dana-Faber Cancer institute explore spheroid and organ-on-chip advancements.

3D models

SYNGENEIC & PDX

As some of the most popular models on the market, Astex Pharmaceuticals explores the challenges of Syngeneic models for rare disease and the panel discusses the benefits and limitations of PDX models to improve translation of immunotherapies against solid tumours